Premium
Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters
Author(s) -
Klamt Barbara,
Schulze Michael,
Thäte Claudia,
Mares Jaroslav,
Goetz Peter,
Kodet Roman,
Scheurlen Wolfram,
Weirich Angela,
Graf Norbert,
Gessler Manfred
Publication year - 1998
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/(sici)1098-2264(199808)22:4<287::aid-gcc4>3.0.co;2-r
Subject(s) - loss of heterozygosity , biology , chromosome , allele , wilms' tumor , cancer research , genetics , carcinogenesis , cancer , pathology , gene , medicine
An extended analysis for loss of heterozygosity (LOH) on eight chromosomes was conducted in a series of 82 Wilms tumors. Observed rates of allele loss were: 9.5% (1p), 5% (4q), 6% (6p), 3% (7p), 9.8% (11q), 28% (11p15), 13.4% (16q), 8.8% (18p), and 13.8% (22q). Known regions of frequent allele loss on chromosome arms 1p, 11p15, and 16q were analyzed with a series of markers, but their size could not be narrowed down to smaller intervals, making any positional cloning effort difficult. In contrast to most previous studies, several tumors exhibited allele loss for multiple chromosomes, suggesting an important role for genome instability in a subset of tumors. Comparison with clinical data revealed a possible prognostic significance, especially for LOH on chromosome arms 11q and 22q with high frequencies of anaplastic tumors, tumor recurrence, and fatal outcome. Similarly, LOH 16q was associated with anaplastic and recurrent tumors. These markers may be helpful in the future for selecting high‐risk tumors for modified therapeutic regimens. Genes Chromosomes Cancer 22:287–294, 1998. © 1998 Wiley‐Liss, Inc.